Yasir Rawjee

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW). The company’s four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE. The company’s journey as an independent entity began in 2019, branching off from Glenmark Pharmaceuticals to focus solely on building an API business. Since then, the API business has charted a strong course and flourished independently to pave the way for a distinctive growth trajectory. FY24 marked a significant milestone for the company, due to a change of ownership from Glenmark Pharmaceuticals to Nirma. The key differentiator for Alivus is its people. The knowledgeable, responsible and inspired team, of almost 2000 employees from 7 nationalities, constantly challenges themselves to forge out-of-the-box solutions. Powered by its world-class manufacturing and research capabilities, Alivus supplies high-quality APIs to more than 700 pharma companies in over 70 countries. As part of its evolving vision, the company is further strengthening its global presence and committing to provide innovative solutions in the API and CDMO space.